DEF: Azenta Sets Annual Meeting Agenda, Seeks Shareholder Votes

Azenta, Inc. announces its Annual Meeting of Shareholders on January 28, 2026, to vote on director elections, executive compensation, an increase in equity plan shares, and auditor ratification.

Summary

• The Annual Meeting of Shareholders will be held virtually on Wednesday, January 28, 2026, at 9:00 a.m. Eastern Time.
• Shareholders will vote on the election of ten directors, a non-binding advisory vote on named executive officer compensation, an amendment to the 2020 Equity Incentive Plan to increase shares reserved for issuance by 2,750,000, and the ratification of PricewaterhouseCoopers LLP as the independent registered accounting firm for the 2026 fiscal year.
• For fiscal year 2025, Azenta reported $594 million in revenue from continuing operations, a 4% year-over-year increase (3% organic growth).
• Adjusted EBITDA from continuing operations was $66 million, with an 11.2% margin, up 310 basis points year-over-year.
• Adjusted Operating Income was $16 million, with a 2.6% margin, up 200 basis points year-over-year.
• Free Cash Flow was $38 million, representing a $26 million improvement over the prior year.
• The B Medical business was reclassified to discontinued operations, and its sale is being pursued to streamline the portfolio.
• The fiscal 2023-2025 Long-Term Incentive Plan (LTIP) achieved 0% of target due to below-threshold performance on cumulative Adjusted EBITDA, cumulative Free Cash Flow, and 3-year average ROIC.
• A material weakness in internal control over financial reporting was identified, leading to revisions in FY2024 and FY2023 financial statements and a clawback of $56,116 in erroneously awarded FY2024 incentive compensation from executive officers.

Sentiment

Score: 5

Explanation: While Azenta shows positive operational improvements and revenue growth, the 0% achievement on the long-term incentive plan, coupled with identified material weaknesses in internal controls and a clawback of executive compensation, indicates underlying problems and poor past performance in key areas. The company is undergoing a transformation, including divesting the B Medical business, which could be positive long-term, but current issues suggest a 'wait and see' approach.

Positives

• Achieved 4% reported revenue growth and 3% organic growth in fiscal year 2025 from continuing operations.
• Delivered significant margin expansion, with Adjusted EBITDA margin up 310 basis points and Adjusted Operating Income margin up 200 basis points year-over-year.
• Generated strong Free Cash Flow of $38 million, a $26 million improvement over the prior year.
• Implemented business simplification through the Azenta Business System, leading to measurable improvements in quality, delivery, and productivity.
• Received over 99% shareholder approval for the 2025 say-on-pay proposal, indicating strong shareholder alignment on executive compensation philosophy.
• Maintains robust corporate governance practices, including a separate Board Chair and CEO, annual director elections, stock ownership guidelines, and a clawback policy.
• The Board of Directors demonstrates strong independence, with nine out of ten director nominees being independent, and 40% representing gender, racial, or ethnic diversity.

Negatives

• The fiscal 2023-2025 Long-Term Incentive Plan (LTIP) achieved 0% of target, failing to meet threshold performance for cumulative Adjusted EBITDA, cumulative Free Cash Flow, and 3-year average ROIC.
• Identified a material weakness in internal control over financial reporting related to the classification of certain costs in the Consolidated Statement of Operations.
• Financial statements for fiscal years 2024 and 2023 required revisions due to immaterial misstatements from classification errors.
• A clawback of $56,116 in erroneously awarded FY2024 incentive compensation was required from executive officers due to the financial revisions.
• Fiscal 2025 Incentive Compensation Plan (ICP) Core Revenue achievement was below target at 85.8%.
• Fiscal 2025 ICP Adjusted EBITDA performance was slightly below plan target at 94.1%.

Risks

• Material weakness in internal control over financial reporting, specifically concerning the classification of costs in the Consolidated Statement of Operations, balance sheet reconciliations, and misclassification of operating expenses.
• Failure to timely and effectively remediate identified material weaknesses in internal controls could impact financial reporting reliability.
• Challenges in achieving aggressive performance targets for incentive compensation plans, as evidenced by the 0% achievement of the FY2023-2025 LTIP.
• Operating in cyclical and volatile industries, which can impact business performance and financial results.
• Potential adverse tax consequences for stock options if adjustments constitute a modification under Section 424(h) of the Code or violate Section 409A.
• Risk of not attracting and retaining exceptional talent if compensation programs are not competitive or perceived as unfair due to clawbacks or underperformance of long-term incentives.

Future Outlook

The company is pursuing the sale of its B Medical business to streamline its portfolio and accelerate revenue growth and profitability in its core businesses. It expects the proposed increase of 2,750,000 shares in the 2020 Equity Incentive Plan reserve to provide sufficient authorization for anticipated stock-based awards for the next four years. The Human Resources and Compensation Committee will seek to recover remaining erroneously awarded compensation during fiscal year 2026, and the Audit Committee will oversee management's remediation plans for material weaknesses throughout fiscal year 2026.

Management Comments

• Our executive compensation program reflects Azenta's commitment to innovation, growth, and delivering value for our customers, employees, and shareholders.
• Attracting and retaining exceptional talent is essential to advancing our strategy and achieving long-term success.
• Fiscal 2025 was a transformative year for Azenta.
• We delivered 4% reported revenue growth and 3% organic growth, alongside significant margin expansion of 310 basis points.
• The results were driven by business simplification through the Azenta Business System, and enhanced execution, which led to measurable improvements in quality, delivery, and productivity.
• We understand the critical importance of sample integrity and offer a broad portfolio of products and services, including automated storage systems, genomic services, consumables, informatics, data software, and sample repository solutions.
• Our global footprint, deep expertise, and leadership positions make us a trusted partner to pharmaceutical, biotechnology, and life sciences research institutions worldwide.

Industry Context

Azenta operates within the life sciences industry, specializing in biological and chemical compound sample exploration and management solutions, automated storage, and genomic services. The company's strategic focus on accelerating impactful breakthroughs and therapies aligns with broader industry trends emphasizing innovation and efficiency in research and development. Its executive compensation program is benchmarked against a peer group of life sciences and related companies, reflecting the competitive landscape for talent and business in this sector.

Comparison to Industry Standards

• The executive compensation program is benchmarked against a peer group of life sciences and related companies, including 10x Genomics, Bio-Techne Corporation, Certara, Inc., Cryoport, Inc., Guardant Health, Inc., Haemonetics Corporation, Maravai LifeSciences Holdings Inc., Medpace Holdings, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., Repligen Corporation, Sotera Health Company, Tandem Diabetes Care, Inc., and Twist Bioscience Corporation.
• The Long-Term Incentive Plan (LTIP) mix was adjusted to 50% Performance Share Units (PSUs) and 50% time-based Restricted Stock Units (RSUs) to better align with life sciences peers and prevailing market practice.
• The payout at threshold performance for the Incentive Compensation Plan (ICP) was increased from 25% to 50% of target to align with prevalent market practice in the life sciences industry and enhance competitiveness.
• Relative Total Shareholder Return (rTSR) for PSUs is compared against a group of 22 companies, including established compensation peers and other life sciences companies with similar market capitalization and revenue (e.g., Cytek Biosciences, Inc., DiaSorin S.p.A., Evotec SE, Fulgent Genetics, Inc., MesaLabs, Inc., Neogen Corporation, Veracyte, Inc.).
• The S&P 1500 Life Sciences Tools & Services Industry Index is used as a benchmark for cumulative Total Shareholder Return (TSR) in performance graphs, aligning comparative stock performance disclosures with a relevant line-of-business index.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Direct impact from voting on director elections, executive compensation, equity plan share increase (potential dilution), and auditor ratification. Financial performance (revenue growth, margin expansion) is positive, but 0% LTIP achievement and internal control issues are concerning. The clawback demonstrates accountability but highlights past misstatements.
• Employees: Impacted by executive compensation structure, equity incentive plan, and potential for future awards. The company emphasizes workforce engagement, diversity, development, and well-being programs.
• Customers: Benefit from the company's mission to accelerate breakthroughs and therapies, and its focus on quality, delivery, and product integrity in life sciences solutions.
• Management: Directly affected by compensation structure, performance targets, and the clawback policy. New CEO and CFO appointments signal a leadership transition and strategic focus.

Next Steps

• Shareholders will vote on the election of directors, executive compensation, equity plan amendment, and auditor ratification at the Annual Meeting on January 28, 2026.
• The Human Resources and Compensation Committee will seek to recover the remaining erroneously awarded compensation from executive officers during fiscal year 2026.
• The Audit Committee will oversee management's remediation plans for material weaknesses in internal control over financial reporting throughout fiscal year 2026.
• Upon shareholder approval of Proposal No. 3, the Company intends to file a registration statement with the SEC covering the 2,750,000 additional shares authorized for issuance under the 2020 Plan.
• Shareholders wishing to submit proposals for the 2027 annual meeting for inclusion in proxy materials must do so by August 18, 2026.
• Shareholders wishing to present proposals at the 2027 annual meeting (not for proxy materials) must submit notice between September 30, 2026, and October 30, 2026.

Key Dates

Recommendation

While Azenta shows positive revenue growth and margin expansion, the 0% achievement on the long-term incentive plan, coupled with identified material weaknesses in internal controls and a clawback of executive compensation, indicates significant operational and governance challenges. The company is undergoing a transformation, including divesting the B Medical business, which could be positive long-term, but current issues suggest a 'wait and see' approach. The proposed increase in equity plan shares, while for incentive purposes, also represents potential dilution. Investors should monitor the remediation of internal control weaknesses and the effectiveness of new management in driving consistent long-term performance before considering a stronger position.

Keywords

Azenta, Proxy Statement, SEC Filing, Corporate Governance, Executive Compensation, Financial Performance, Life Sciences, Genomics, Sample Management, Equity Incentive Plan, Board of Directors, Audit Committee, ESG, Risk Management, Shareholder Meeting, PricewaterhouseCoopers, Clawback Policy, Internal Controls, NASDAQ